Sector: MedicalShire Pharmaceuticals Group plc (NASDAQ: SHPGY)
Ranking History
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 216 |
Technical : | 50 |
Performance : | 133 |
Overall: | 128 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 154 |
Technical : | 43 |
Performance : | 153 |
Overall: | 89 |
Number of Stocks: | 306 |
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 153 |
Technical : | 93 |
Performance : | 210 |
Overall: | 168 |
Number of Stocks: | 306 |
Headlines
- MEZADVICE(TM)* helps patients stay on track
Nov 17, 2009 07:03 AM | SHPGY
- MEZAVIS(MC)* aide les patients à demeurer fidèles à leur traitement
Nov 17, 2009 07:01 AM | SHPGY
- Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
Nov 16, 2009 09:01 AM | SHPGY
- Shire Reports Findings From an Analysis Examining Emotional Lability in Children With ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
Nov 12, 2009 09:02 AM | SHPGY
- Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
Nov 11, 2009 09:01 AM | SHPGY
- Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide
Nov 09, 2009 09:02 AM | SHPGY
- Porter Novelli Wins Gold from Medical Marketing & Media for Best Unbranded TV Ad
Nov 04, 2009 09:38 AM | OMC, SHPGY
- Shire Extends Agreement with Medidata Solutions for Trial Planning Products
Nov 04, 2009 08:30 AM | SHPGY
- FDA Grants Priority Review for Shire's velaglucerase alfa for Type 1 Gaucher Disease
Nov 04, 2009 07:03 AM | SHPGY
- SHIRE PLC - FDA Grants Priority Review for Shire’s velaglucerase
Nov 04, 2009 07:02 AM | SHPGY
- Evening Standard, London, Market Report Column
Aug 19, 2009 03:50 PM | BTI, HBC, JPM, LYG, SANYY, SHPGY
- Daily Mail, London, Market Report Column
Aug 18, 2009 04:54 PM | BCS, IBM, LGGNY, LYG, SHPGY, TEO
- Daily Mail, London, Market Report Column - Apr 24 2009 3:54PM
Apr 24, 2009 03:53 PM | GSK, MAKSY, PFE, SHPGY
- Shire Opens Office in Japan, Appoints New MD
Feb 20, 2009 02:30 PM | SHPGY
- Movers: AIG, Lehman, Healthways, LDK Solar, Noven Pharma
Aug 26, 2008 10:55 AM | AIG, AMD, BRCM, FNM, FRE, GILT
- Impax Laboratories Commences Shipment of Generic Adderall XR® Capsules, 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg
Oct 01, 2009 03:54 PM | IPXL, SHPGY
- Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
Aug 24, 2009 08:01 AM | SHPGY
- Shire Initiates Two Adult ADHD Outreach Programs
Aug 17, 2009 09:01 AM | SHPGY
- Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
Aug 03, 2009 02:01 AM | SHPGY
- FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents
Jul 28, 2009 02:01 AM | SHPGY
- Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
Jul 22, 2009 09:03 AM | SHPGY
- Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Jul 16, 2009 02:01 AM | SHPGY
- Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
Jul 06, 2009 03:02 PM | SHPGY
- Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
Jul 01, 2009 09:03 AM | SHPGY
- FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
Jun 01, 2009 09:01 AM | SHPGY
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
SHPGY
|
Compare to S&P
|
| YTD |
33.54 %
|
10.31 %
|
| 4 Weeks |
21.59 %
|
20.95 %
|
| 12 Weeks |
16.23 %
|
9.07 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -53.12 %
|
|
EPS Growth in Last Year: -36.84 %
|
|
Sales Growth in Last Quarter: -22.96 %
|
|
Sales Growth in Last Quarter: -18.77 %
|
|
